- Health Canada has authorized PrUpgolyv (golimumab), a biosimilar to Simponi (golimumab), for patients with chronic inflammatory autoimmune diseases
- Developed by JAMP Pharma Group under its BioJAMP® division, the therapy strengthens its growing immunology-focused biosimilars pipeline
- Available in prefilled syringes and autoinjectors (50 mg and 100 mg), the drug aims to improve access to cost-effective biologic therapies in Canada
- Patients will be supported through the JAMP Care™ program, offering reimbursement, education, and treatment assistance to enhance access and outcomes
Takeaways:
Health Canada has authorized PrUpgolyv (golimumab injection), giving Canada its first Simponi biosimilar and further extending JAMP Pharma’s BioJAMP immunology franchise.
Offered in 50 mg and 100 mg prefilled syringes and autoinjectors and backed by the JAMP Care program for reimbursement, onboarding, and education support, PrUpgolyv is positioned to lower biologic costs for patients with chronic inflammatory autoimmune diseases while reinforcing JAMP’s role as a leading domestic biosimilars player.
Source: PRnewswire
